Asset Details
Do you wish to reserve the book?
Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity
Do you wish to request the book?
Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity
2011
Overview
In this trial, one intravitreal injection of bevacizumab was administered to treat retinopathy of prematurity of stage 3+. Bevacizumab was more effective than conventional laser therapy in preventing recurrence of neovascularization in infants with zone I but not zone II posterior retinopathy.
Retinopathy of prematurity is a neovascular retinal disorder of childhood that causes loss of vision by means of macular dragging and retinal detachment. It is a leading cause of childhood blindness in the United States and other highly industrialized nations, occurring primarily in infants of low birth weight (≤1250 g; mean, 700 g).
1
The incidence of blindness in infants due to retinopathy of prematurity is relatively low, about 1 case in 820 infants,
2
because of good neonatal care and appropriate screening and treatment.
1
The disorder is a major cause of childhood blindness in developing countries, manifesting in larger premature infants . . .
Publisher
Massachusetts Medical Society
Subject
Angiogenesis Inhibitors - adverse effects
/ Angiogenesis Inhibitors - therapeutic use
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized
/ Babies
/ Biological and medical sciences
/ Female
/ Humans
/ Laser Therapy - adverse effects
/ Male
/ Retina
/ Retinopathy of Prematurity - classification
/ Retinopathy of Prematurity - drug therapy
